Results 231 to 240 of about 22,239 (295)

Subtype-Specific Causal Effects of Antidiabetic Drug Targets on Ovarian Cancer: Mendelian Randomization and Colocalization Evidence. [PDF]

Int J Womens Health
Tang E, Zeng J, Shi X, Wang Y, Sun Y, Wu L.   +5 more
europepmc   +1 more source

Edible Yellow Mealworm-Derived Antidiabetic Peptides: Dual Modulation of α-Glucosidase and Dipeptidyl-Peptidase IV Inhibition Revealed by Integrated Proteomics, Bioassays, and Molecular Docking Analysis. [PDF]

Foods
Zhu Y, Zhou E, Tang Y, Li Q, Wu L.
europepmc   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists and Prior Major Adverse Limb Events in Patients With Diabetes.

JAMA Netw Open
Hsiao FC, Hsu TJ, Hsieh YJ, Tung YC, Chen DY, Lin CP, Chen SW, Chu PH.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors

Bioorganic & Medicinal Chemistry Letters, 2004
Amides derived from fluorinated pyrrolidines and 4-substituted cyclohexylglycine analogues have been prepared and evaluated as inhibitors of dipeptidyl dipeptidase IV (DP-IV). Analogues which incorporated (S)-3-fluoropyrrolidine showed good selectivity for DP-IV over quiescent cell proline dipeptidase (QPP).
Charles G, Caldwell, Ping, Chen, Jiafang, He, Emma R, Parmee, Barbara, Leiting, Frank, Marsilio, Reshma A, Patel, Joseph K, Wu, George J, Eiermann, Aleksandr, Petrov, Huaibing, He, Kathryn A, Lyons, Nancy A, Thornberry, Ann E, Weber   +13 more
openaire   +3 more sources

A potent dipeptide inhibitor of dipeptidyl peptidase IV

Bioorganic & Medicinal Chemistry Letters, 1998
A series of novel potent inhibitors of dipeptidyl peptidase IV (DPP-IV) has been developed. A brief structure-activity relationship of the inhibitors was investigated. The dipeptide TSL-225, tryptophyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, was identified with the critical structure for the inhibitory activity.
M, Yamada, C, Okagaki, T, Higashijima, S, Tanaka, T, Ohnuki, T, Sugita   +5 more
openaire   +2 more sources

Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV

International Journal of Immunopharmacology, 1997
Dipeptidyl peptidase IV (DP IV, CD26) is a serine exoprotease which selectively cleaves the penultimate proline residue of polypeptides. This enzyme is also expressed as a surface marker on activated T cells. In order to assess the relevance of DP IV in immunological disorders, we evaluated the in vivo effects of specific DP IV inhibitors using two ...
S, Tanaka, T, Murakami, H, Horikawa, M, Sugiura, K, Kawashima, T, Sugita   +5 more
openaire   +2 more sources

Recent patents of dipeptidyl peptidase IV inhibitors

Expert Opinion on Therapeutic Patents, 2011
The serine exopeptidase DPP IV is a dual protein able to work as an enzyme and an interacting protein. The incretin molecules glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are hydrolyzed by DPP IV into inactive forms, which are unable to promote insulin secretion.
Laura, Mendieta, Teresa, Tarrago, Ernest, Giralt   +2 more
openaire   +2 more sources

Dipeptide Phosphonates as Inhibitors of Dipeptidyl Peptidase IV

Journal of Medicinal Chemistry, 1994
A series of dipeptides which contained phosphonate analogs of proline and piperidine-2-carboxylic acid (homoproline) have been synthesized and tested as inhibitors of DPP-IV. The rates of inhibition of DPP-IV by these compounds are moderate, but the inhibitors are quite specific. The best inhibitor in the series is Ala-PipP(OPh-4-Cl)2 (13), which has a
B, Boduszek, J, Oleksyszyn, C M, Kam, J, Selzler, R E, Smith, J C, Powers   +5 more
openaire   +2 more sources

Azetidine-Based Inhibitors of Dipeptidyl Peptidase IV (DPP IV)

Current Topics in Medicinal Chemistry, 2007
The structure-activity relationships of azetidine-based DPP IV inhibitors will be discussed in detail in the following review. The azetidine-based DPP IV inhibitors can be divided into three main subtypes, the 2-cyanoazetidines, 3-fluoroazetidines and 2-ketoazetidines.
Dana, Ferraris, Sergei, Belyakov, Weixing, Li, Eddie, Oliver, Yao-Sen, Ko, David, Calvin, Susan, Lautar, Bert, Thomas, Camilo, Rojas   +8 more
openaire   +2 more sources

Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor

Australasian Journal of Dermatology, 2011
ABSTRACTPsoriatic patients have a higher prevalence of diabetes mellitus type 2 (DM). Since dipeptidyl peptidase IV (DPP‐IV) dysregulation is present in DM and psoriasis, DPP‐IV inhibitors have been proposed as therapeutic agents for both conditions. We report a psoriasiform eruption induced by sitagliptin, a DPP‐IV inhibitor. The role of DPP‐IV in the
Albert, Mas-Vidal, Jorge, Santos-Juanes, Altea, Esteve-Martinez, Luis, Caminal-Montero, Pablo, Coto-Segura   +4 more
openaire   +2 more sources